Austar Lifesciences' low P/S ratio may be a buying opportunity, but its poor financial performance and declining revenue are concerning. Despite higher medium-term revenue growth rates than the industry average, the continued decline in stock price and P/S ratio indicates potential risks.
Investors fear the company may underperform the broader industry soon, despite strong revenue growth. Shareholders think recent performance has peaked, accepting lower selling prices. Underlying risks to profitability are pressuring the P/S ratio.
奧星生命科技股票討論區
暫無評論